Centrix Pharma Solutions, a UK-based Contract Development Manufacturing Organisation (CDMO), has appointed Dr Nathalie Huther as Senior Vice President of Business Development and Commercial, to support its commercial growth and strengthen its international market presence.

With more than 20 years’ experience in the life sciences and pharmaceutical sectors, Huther brings extensive expertise in international business development, commercial strategy and strategic partnerships. Her appointment will support Centrix’s ambitions to expand its customer base, strengthen existing relationships, and build its position as a specialist development and manufacturing partner for pharmaceutical and biotechnology companies.

Huther has held senior commercial roles across pharmaceutical services and technology businesses, including Arcinova, Nanoform, Quotient Sciences and Sai Life Sciences. At Arcinova, she led the development and expansion of the EMEA business, driving substantial revenue growth and strengthening the company's market position ahead of its acquisition by Quotient Sciences in 2021.

Most recently, as Chief Commercial Officer at HFR (High Force Research), an independent UK CDMO, she established and developed the commercial function, strengthened the company’s market positioning and identified opportunities for international growth.

Huther was also recognised as a Northern Powerhouse Export Champion by the UK Department for International Trade (DIT) in both 2020 and 2021.

In her new role, Huther will lead Centrix’s business development and commercial strategy, focusing on expanding its international reach, developing strategic customer relationships and identifying new opportunities. She will work closely with the company’s technical and operational teams to align commercial priorities with Centrix’s expertise in formulation development, analytical services and GMP clinical manufacturing.

Commenting on her appointment, Huther said: "Centrix has strong technical expertise in drug product development and clinical manufacturing, with a specific ability to support companies with complex formulation and development challenges. I was attracted by the opportunity to build on these strengths and help realise the company’s commercial potential.

“There is a clear opportunity for specialist CDMOs that combine scientific expertise with flexibility and a collaborative approach. I’m looking forward to working with the team to strengthen our international presence, develop lasting customer partnerships, and help more innovative medicines progress towards clinical development.”

Chris Davison, CEO of Centrix Pharma Solutions, said: "Over the past few years, we’ve focused on building Centrix’s drug product development and clinical manufacturing capabilities. With ambitious plans for the business, now is the right time to strengthen our commercial leadership and build on those foundations.

“Nathalie brings a valuable combination of scientific understanding, international commercial experience and a proven track record of business growth. Importantly, she shares our approach to business development, which is about understanding our clients’ challenges, identifying where we can genuinely add value and building long-term relationships.

“Her appointment will help us sharpen our commercial focus, expand our international reach and engage with clients earlier in their development programmes, bringing together the right expertise from across Centrix and our wider partnerships. We’re delighted to welcome her to the team.”